NCT06853314 An Effectiveness Trial of the PrEP for WINGS Study
| NCT ID | NCT06853314 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 307 participants |
| Start Date | 2026-04-09 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 307 participants in total. It began in 2026-04-09 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
(Effectiveness Aim 1) To test the comparative effectiveness of PreP for WINGS versus PrEP alone on primary outcomes of increasing PrEP initiation measured by self-report/medical records, recent adherence and longer-term adherence by self-report/medical records over the 6-month follow-up; and secondary outcomes of decreasing IPV, hazardous drinking, recidivism, and HIV risks. (Moderation Aim 2) To test if the effectiveness of WINGS+PrEP on study outcomes is moderated by key participant subgroups based on race/ethnicity, sexual orientation, age, education, incarceration history, IPV severity, substance use disorders (SUDs), digital access and literacy, housing stability, and medical mistrust.
Eligibility Criteria
Inclusion Criteria: Identify as a cis-gender woman Aged 18 or older HIV-negative Previous engagement with the criminal legal system or child protective services. Meet criteria for hazardous alcohol use Previous experience of intimate partner veiolence Report not taking PrEP in the past 90 days Recent experiences of HIV risk due to HIV risk exposure Exclusion Criteria: Ability to speak and understand English is not sufficient to participate in assessments or intervention sessions. Inability to complete informed consent process due to a psychiatric or cognitive impairment (assessed by the Mini Folstein exam)
Contact & Investigator
Anindita Dasgupta, MPH, PhD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT06853314 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06853314 currently recruiting?
Yes, NCT06853314 is actively recruiting participants. Contact the research team at ad3341@cumc.columbia.edu for enrollment information.
Where is the NCT06853314 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06853314 clinical trial?
NCT06853314 is sponsored by Columbia University. The principal investigator is Anindita Dasgupta, MPH, PhD at Columbia University. The trial plans to enroll 307 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.